[go: up one dir, main page]

KR950028772A - Indomethacin external preparation and its manufacturing method - Google Patents

Indomethacin external preparation and its manufacturing method Download PDF

Info

Publication number
KR950028772A
KR950028772A KR1019940009330A KR19940009330A KR950028772A KR 950028772 A KR950028772 A KR 950028772A KR 1019940009330 A KR1019940009330 A KR 1019940009330A KR 19940009330 A KR19940009330 A KR 19940009330A KR 950028772 A KR950028772 A KR 950028772A
Authority
KR
South Korea
Prior art keywords
indomethacin
poloxamer
lower alcohols
purified water
tocopherol acetate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019940009330A
Other languages
Korean (ko)
Other versions
KR0142900B1 (en
Inventor
김운장
이한구
Original Assignee
김운장
대화제약 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 김운장, 대화제약 주식회사 filed Critical 김운장
Priority to KR1019940009330A priority Critical patent/KR0142900B1/en
Publication of KR950028772A publication Critical patent/KR950028772A/en
Application granted granted Critical
Publication of KR0142900B1 publication Critical patent/KR0142900B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

본 발명은 활성성분으로서 인도메타신을 함유하는 새로운 인도메타신 외용제제 및 그 제조방법에 관한 것으로, 겔화기제로서 폴록사머 유도체를 함유하여 피부의 자극을 최소화하며, 약물의 피부 투과율을 높인 새로운 인도메타신 겔제제를 제공한다.The present invention relates to a new indomethacin external preparation containing indomethacin as an active ingredient and a method for preparing the same, and a new indomethac which contains poloxamer derivatives as a gelling agent to minimize skin irritation and increases skin permeability of drugs. Provide a sour gel formulation.

본 발명은 또한 인도메타신과 폴록사머 유도체를 가열, 용융시키고, 따로 저급알코올류에 용해가능한 성분을 용해시켜 상기 용융액에 가하고, 여기에 수용성 물질을 녹인 정제수 또는 완충액을 추가로 가하여 인도메타신겔제제를 제조하는 방법을 제공한다.The present invention also heats and melts indomethacin and poloxamer derivatives, and separately dissolves soluble components in lower alcohols, adds to the melt, and further adds purified water or a buffer in which water-soluble substances are added to indomethacin gel formulation. It provides a method of manufacturing.

Description

인도메타신 외용제제 및 그 제조방법Indomethacin external preparation and its manufacturing method

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 PH에 따른 본 발명의 겔제제의 피부 투과율을 나타내는 그래프이다.1 is a graph showing the skin permeability of the gel preparation of the present invention according to PH.

Claims (8)

활성성분으로서 인도메타신; 및 폴록사머 407; 저급알코올류; 토코페롤 아세테이트 0-2.0%; 멘톨오일 0-0.1%; 통상의 보조제와 정제수 또는 완충액을 균질하게 혼합시켜서 제조된 인도메타신 겔제제.Indomethacin as active ingredient; And poloxamer 407; Lower alcohols; Tocopherol acetate 0-2.0%; Menthol oil 0-0.1%; An indomethacin gel preparation prepared by homogeneously mixing a conventional adjuvant with purified water or a buffer solution. 제1항에서, 인도메타신 0.1-3.0%; 폴록사머 407 20.0-30.0%;저급알코올류 5.0-20.0%;토코페롤 아세테이트 0-2.0%; 멘톨오일 0-1.0%를 함유하는 인도메타신 겔제제.The method of claim 1, wherein indomethacin 0.1-3.0%; Poloxamer 407 20.0-30.0%; lower alcohols 5.0-20.0%; tocopherol acetate 0-2.0%; Indomethacin gel formulation containing 0-1.0% of menthol oil. 제1항 또는 제2항에서, 용해보조제로 프로필렌글리콜 또는 폴리에틸렌글리콜류에서 선택된 용해보조제 5.0-20.0%를 함유하는 인도메타신 겔제제.The indomethacin gel preparation according to claim 1 or 2, comprising 5.0-20.0% of a dissolution aid selected from propylene glycol or polyethylene glycol as a dissolution aid. 제1항 또는 제2항에서, 인도메타신 0.1-3.0%, 폴록사머 407 20.0-30.0%, 저급알코올류 5.0-20.0%, 프로필렌글리콜 또는 폴리에틸렌글리콜류에서 선택된 용해보조제 5.0-20.0%, 염화나트륨 0.1-1.0%, 토고페롤 아세테이트 0-2.0%, 멘톨오일 0-1.0%를 함유하는 인도메타신 겔제제.The dissolving aid according to claim 1 or 2 selected from indomethacin 0.1-3.0%, poloxamer 407 20.0-30.0%, lower alcohols 5.0-20.0%, propylene glycol or polyethylene glycols, sodium chloride 0.1 Indomethacin gel formulation containing -1.0%, togoferol acetate 0-2.0%, menthol oil 0-1.0%. 인도메타신과 폴록사머 407을 가열, 용융시키고, 여기에 토코페롤 아세테이트 0-2.0% 및 멘톨오일 0-1.0%를 녹인 저급알코올류를 가하고, 다시 정제수 또는 완충액을 가하여 균질하게 혼합시켜서 인도메타신 겔제제를 제조하는 방법.Indomethacin and poloxamer 407 were heated and melted, and low alcohols dissolved in 0-2.0% of tocopherol acetate and 0-1.0% of menthol oil were added thereto, followed by further mixing with purified water or buffer solution to form indomethacin gel. How to prepare. 제5항에서, 인도메타신 0.1-3.0%; 폴록사머 407 20.0-30.0%; 저급알코올류 5.0-20.0%; 토코페롤 아세테이트 0-2.0%; 멘톨오일 0-1.0%;를 함유하는 인도메타신 겔제제를 제조하는 방법.The method of claim 5, wherein indomethacin 0.1-3.0%; Poloxamer 407 20.0-30.0%; Lower alcohols 5.0-20.0%; Tocopherol acetate 0-2.0%; Indomethacin gel preparation containing menthol oil 0-1.0%. 제5항 또는 제6항에서, 폴리에틸렌글리콜류 5.0-20.0%, 염화나트륨 0.1-1.0%에서 선택된 1종 이상의 물질을 정제수 또는 완충액에 용해시켜 가한 인도메타신 겔제제를 제조하는 방법.The method for preparing indomethacin gel preparation according to claim 5 or 6, wherein one or more substances selected from 5.0-20.0% polyethylene glycol and 0.1-1.0% sodium chloride are dissolved in purified water or a buffer solution. 제5항 또는 제6항에서, 인도메타신 0.1-3.0%과 폴록사머 407 20.0-30.0%를 가열, 용융시키고, 따로 저급알코올류 5.0-20.0%에 프로필렌글리콜 5.0-20.0%, 토코페롤 아세테이트 0-2.0%, 멘톨오일 0-1.0%에서 선택된 1종 이상의 물질을 용해시켜 가하고, 염화나트륨 0.1-1.0%, 폴리에틸렌글리콜 5.0-20.0%(단, 프로필렌글리콜이 선택되지 않은 경우 선택될 수 있다)에서 선택된 1종 이상의 물질을 정제수 또는 완충액에 용해시켜 가한 인도메타신 겔제제를 제조하는 방법.The method according to claim 5 or 6, 0.1-3.0% indomethacin and 20.0-30.0% poloxamer 407 is heated and melted separately, 5.0-20.0% lower alcohols 5.0-20.0% propylene glycol 5.0-20.0%, tocopherol acetate 0- 1% or more selected by dissolving 2.0%, menthol oil 0-1.0% and adding 1, selected from sodium chloride 0.1-1.0%, polyethylene glycol 5.0-20.0% (if propylene glycol is not selected) A method for preparing an indomethacin gel preparation by dissolving more than one substance in purified water or a buffer. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019940009330A 1994-04-29 1994-04-29 Indomethacin external preparation Expired - Fee Related KR0142900B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019940009330A KR0142900B1 (en) 1994-04-29 1994-04-29 Indomethacin external preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019940009330A KR0142900B1 (en) 1994-04-29 1994-04-29 Indomethacin external preparation

Publications (2)

Publication Number Publication Date
KR950028772A true KR950028772A (en) 1995-11-22
KR0142900B1 KR0142900B1 (en) 1998-07-15

Family

ID=19382136

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019940009330A Expired - Fee Related KR0142900B1 (en) 1994-04-29 1994-04-29 Indomethacin external preparation

Country Status (1)

Country Link
KR (1) KR0142900B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294750A (en) * 2020-10-29 2021-02-02 广东药科大学 A kind of indomethacin micelle composite microneedle and preparation method thereof

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112294750A (en) * 2020-10-29 2021-02-02 广东药科大学 A kind of indomethacin micelle composite microneedle and preparation method thereof
CN112294750B (en) * 2020-10-29 2023-06-20 广东药科大学 A kind of indomethacin micelle composite microneedle and preparation method thereof

Also Published As

Publication number Publication date
KR0142900B1 (en) 1998-07-15

Similar Documents

Publication Publication Date Title
UY24210A1 (en) STICK-FREE, CLEAR OR TRANSLUCENT GEL OR ANTI-TRANSPIRANT BAR COMPOSITION AND METHOD OF MANUFACTURING
US4794117A (en) Process for solubilizing active ingredients and the thus-obtained pharmaceutical compositions
ES2118677T3 (en) A COMPOSITION THAT INCLUDES A DISSOLVED ACTIVE AGENT IN A GLASS TRAINING VEHICLE AND A PROCEDURE FOR PREPARATION.
PE20000972A1 (en) RAPIDLY DISSOLVING ORALLY CONSUMABLE FILMS
DE60045153D1 (en) PREPARATIONS FOR PERCUTANEOUS ABSORPTION
NO20005431D0 (en) Gellable pharmaceutical preparations
BR9507640A (en) Process for stabilizing duocarmicide derivatives and pharmaceutical composition
BR9702362A (en) New stable liquid formulas based on paracetamol and its preparation.
DK0974350T3 (en) Tranilast-containing composition for external application and method for preparing it
BR9906735A (en) Aqueous liquid pharmaceutical composition
CA2204769A1 (en) Hemorrhoidal compositions and method of use
ATE77050T1 (en) EMULSION OF GEL PARTICLES AND COMPOSITION CONTAINING THEM.
DE59108530D1 (en) Antimicrobial agents and substituted 2-cyclohexan-1-yl-amine derivatives and their preparation
GEP20002069B (en) Taxoid Based Pharmaceutical Compositions and Method for its Production
CA1309025C (en) Topical preparation containing ofloxacin
BR9909636A (en) Process for preparing a formulation, and, formulation
MX173607B (en) CRYSTALLINE ANTIPERSPIRANT AND METHOD FOR ITS PREPARATION
ES2112567T3 (en) PROCEDURES AND COMPOSITIONS FOR ADMINISTERING FRAGRANCES.
DK0801559T3 (en) Process for the preparation of oral dosage forms containing a beta-lactam antibiotic
CA2153549A1 (en) New benzothiadiazine derivative, process for preparing the same and pharmaceutical compositions containing said derivative
TR200100896T2 (en) Substituted propanol derivatives, methods of manufacture, drugs containing compositions, their use
RU2216549C2 (en) Piperazine-cyclodextrin complex and medicinal agent containing indicated complex
KR950028772A (en) Indomethacin external preparation and its manufacturing method
ES2192241T3 (en) STABLE LIGHT PROTECTION COMPOSITIONS CONTAINING GLUCOSE TENSIOACTIVE DERIVATIVES AND UV SOLUBLE FILTERS IN WATER.
PE20030545A1 (en) RIBAVIRIN SYRUP FORMULATIONS

Legal Events

Date Code Title Description
A201 Request for examination
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20030326

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20040405

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20040405

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000